Platinum –Based Anti Neoplastic Drugs and Hematotoxicity: Challenges in Cancer Treatmemt

Platinum-based chemotherapy agents, such as cisplatin, carboplatin, and oxaliplatin, are essential in cancer treatment due to their ability to disrupt DNA replication and induce the death of tumor cells. However, their use is often linked with significant hematologic toxicities, particularly myelosuppression, which can lead to conditions like anemia, neutropenia, and thrombocytopenia. These side effects may require dose adjustments, treatment delays, and increase the likelihood of infections and bleeding complications. This article delves into the mechanisms of hematotoxicity linked to platinum-based treatments, including bone marrow suppression, oxidative damage, and DNA crosslinking, all of which hinder normal blood cell production. It also reviews various management strategies, such as modifying drug doses, providing supportive treatments (e.g., G-CSF, erythropoietin-stimulating agents, and transfusions), and conducting regular hematologic monitoring. Ongoing research is focused on improving drug formulations, optimizing combination therapies, and developing protective strategies to reduce toxicity while preserving the drugs’ therapeutic effects. A personalized approach to chemotherapy may reduce hematologic side effects and enhance patient outcomes in cancer care.